A novel strategy for developing a tetravalent vaccine (dvac) against dengue utilizing conserved regions from all DENV proteins
- 16 February 2022
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 164, 105447
Abstract
No abstract availableKeywords
Funding Information
- Higher Education Commission Pakistan
This publication has 36 references indexed in Scilit:
- Prediction of IL4 Inducing PeptidesJournal of Immunology Research, 2013
- Attenuated Vaccines Can Recombine to Form Virulent Field VirusesScience, 2012
- Immune epitope database analysis resourceNucleic Acids Research, 2012
- Development of dengue DNA vaccinesVaccine, 2011
- Cross-Reactivity and Expansion of Dengue-Specific T cells During Acute Primary and Secondary Infections in HumansScientific Reports, 2011
- Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responsesVaccine, 2011
- Peptide binding predictions for HLA DR, DP and DQ moleculesBMC Bioinformatics, 2010
- Immunodominant T-cell responses to dengue virus NS3 are associated with DHFProceedings of the National Academy of Sciences, 2010
- Human TLR3 recognizes dengue virus and modulates viral replicationin vitroCellular Microbiology, 2009
- CAIcal: A combined set of tools to assess codon usage adaptationBiology Direct, 2008